Real‐world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers

Documenti analoghi

• Social media responses to the approval of lecanemab in Japan: sentiment analysis
  di: Kenichiro Sato, et al.
  Pubblicazione: (2024)
• Blood‐based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost‐effectiveness in Alzheimer's disease prevention studies
  di: Kenichiro Sato, et al.
  Pubblicazione: (2025)
• Quantifying the societal impact of disease‐modifying therapies in Alzheimer's disease: a cost savings‐based approach
  di: Kenichiro Sato, et al.
  Pubblicazione: (2025)
• Nucleus accumbens degeneration in spinocerebellar ataxia type 2: a preliminary study
  di: Kenjiro Nakayama, et al.
  Pubblicazione: (2024)
• Analyzing Response Rates and Respondent Demographics in Online Surveys Assessing Public Perception of Alzheimer’s Disease‐Modifying Therapies
  di: Saki Nakashima, et al.
  Pubblicazione: (2024)